Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;21(10):711–718. doi: 10.1002/clc.4960211004

Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): Atrial fibrillation, quinidine, procainamide, et cetera, and instant death

J O'Neal HUMPHRIES 1,✉
PMCID: PMC6656189  PMID: 9789690

Abstract

Primum non nocere. Atrial fibrillation (AF) occurs commonly following coronary artery bypass graft surgery, although new onset atrial fibrillation in this setting is usually transient. When AF reverts or is converted to sinus rhythm it is unlikely to recur, whether or not the patient takes preventive medication. As no benefit (and sometimes increased risk) associated with reduced mortality or morbidity in this setting has been reported for antiarrhythmic agents, standard treatment should consist of observation or control of ventricular response with an appropriate agent until AF relapses to sinus rhythm. If an antiarrhythmic agent, especially a class I agent, is used because of persistent or recurrent AF in the early postoperative period, heart rhythm should be monitored as long as the class I agent is administered and treatment initiated if an un‐dersirable rhythm develops. Atrial fibrillation in other clinical settings in patients with structural heart disease presents a more difficult management problem. Class I agents are reported to be associated with an increased risk of death, despite an efficacious effect of maintaining sinus rhythm. Amiodarone is reported to be well tolerated with respect to the cardiovascular system, but unacceptable noncardiac effects are reported. A safe amiodarone‐like agent is greatly needed. Atrial fibrillation in patients with no structural heart disease is not discussed in this presentation.

Keywords: atrial fibrillation, coronary artery bypass graft surgery, postoperative care, antiarrhythmic agents, instant death

Full Text

The Full Text of this article is available as a PDF (880.9 KB).

References

  • 1. Vaughn Williams EM: Classification of antiarrhythmic drugs. In Symposium on Cardiac Arrhythmias (Eds. Sandoe E, Flensted‐Jensen E, Olesen KH.), p. 449–472. Sodertalje, Sweden: AB Astra, 1970. [Google Scholar]
  • 2. Vaughn Williams EM: Classification of anti‐arrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 82: 1932–1939 [DOI] [PubMed] [Google Scholar]
  • 3. Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N: Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Int J Cardiol 1997; 58: 135–140 [DOI] [PubMed] [Google Scholar]
  • 4. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL: Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56: 539–549 [DOI] [PubMed] [Google Scholar]
  • 5. Gaylard E: Changing incidence of atrial fibrillation following coronary artery bypass grafting: A retrospective analysis. Br J Clin Pract 1996; 50: 164–165 [PubMed] [Google Scholar]
  • 6. Matthew JP, Parks R, Savino JS, Friedman AS, Koch C, Manago DT, Browner WS: Atrial fibrillation following coronary artery by‐pass graft surgery: Predictors, outcomes, and resource utilization. J Am Med Assoc 1996; 276: 300–306 [PubMed] [Google Scholar]
  • 7. Ommen SR, Odell JA, Stanton MS: Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336: 1429–1434 [DOI] [PubMed] [Google Scholar]
  • 8. Dagud EG, Strickberger SA, Man KG, Goyal R, Deeb GM, Boiling SF, Pagani FD, Bitar C, Meissner MD, Morady F: Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337: 1785–1791 [DOI] [PubMed] [Google Scholar]
  • 9. Frost L, Molgaard H, Christiansen EH, Hjortholm K, Paulsen PK, Thomsen PEB: Atrial fibrillation and flutter after coronary artery bypass surgery: Epidemiology, risk factors and prevention trials, Int J Cardiol 1992; 36: 253–261 [DOI] [PubMed] [Google Scholar]
  • 10. Viskin S, Barron HV, Olgin JE, Hellet K, Scheinman MM: The treatment of atrial fibrillation: Pharmacologic and nonpharmacologic strategies. Curr Probl Cardiol 1997; 22: 44–108 [DOI] [PubMed] [Google Scholar]
  • 11. Page PL, Pym J: Atrial fibrillation following cardiac surgery: Canadian Cardiovascular Society Consensus Conference on Atrial Fibrillation. Can J Cardiol 1996; 12A: 40A–44A [PubMed] [Google Scholar]
  • 12. Yilmaz AT, Demirkilic U, Arslan M, Kurulay E, Ozal E, Tatar H, Ozturk O: Long‐term prevention of atrial fibrillation after coronary artery bypass surgery: Comparison of quinidine, verapamil, and amiodarone in maintaining sinus rhythm. J Cardiac Surg 1996; 11: 61–64 [DOI] [PubMed] [Google Scholar]
  • 13. Yilmaz AT, Demirkilic U, Kuralay E, Arslan M, Cicek S, Ozal E, Bingol H, Tatar H, Ozturk OY: Long‐term prevention of atrial fibrillation after coronary artery surgery. Panminerva Med 1997; 39: 103–105 [PubMed] [Google Scholar]
  • 14. Landymore RW, Howell F: Recurrent arrhythmias following treatment for postoperative atrial fibrillation after coronary bypass operations. Eur J Cardiothor Surg 1991; 5: 436–439 [DOI] [PubMed] [Google Scholar]
  • 15. Hammon JW, Wood A, Prager R, Wood M, Muirhead J, Bender H: Perioperative beta blockade with propranolol: Reduction in myocardial oxygen demands and incidence of atrial and ventricular arrhythmias. Ann Thorac Surg 1984; 38: 363–367 [DOI] [PubMed] [Google Scholar]
  • 16. Janssen J, Loomans L, Harink J, Taams M, Brunninkhuis L, van der Starve P, Kootstra G: Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: A randomized open trial. Angiology 1986; 37: 601–609 [DOI] [PubMed] [Google Scholar]
  • 17. Andrews TC, Reimold SC, Berlin JA, Amman EM: Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta‐analysis of randomized control trials. Circulation 1991; 84: (suppl III) III236–III244 [PubMed] [Google Scholar]
  • 18. Laub GW, Janeira L, Muralidharan S, Riebman JB, Chen C, Neary M, Fenandez J, Adkins MS, McGrath LB: Prophylactic procainamide for prevention of atrial fibrillation after coronary artery by‐pass grafting: A placebo‐crontolled pilot study. Crit Care Med 1993; 21: 1474–1478 [DOI] [PubMed] [Google Scholar]
  • 19. Gold MR, O'Gara FT, Buckley MJ, DeSanctis RW: Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol 1998; 78: 975–979 [DOI] [PubMed] [Google Scholar]
  • 20. Nurozler F, Tokgozoglu L, Pasaoglu I, Boke E, Ersoy U, Bozer AY: Atrial fibrillation after coronary artery bypass surgery: Predictors and the role of MgSO4 replacement. J Cardiol Surg 1996; 11: 421–427 [DOI] [PubMed] [Google Scholar]
  • 21. Beggs VL, Birkemeyer NJ, Nugent WC, Dacey LJ, O'Connor GT : Factors related to rehospitalization within thirty days of discharge‐after coronary artery pass grafting. Best Practices and Benchmarking I Healthcare 1996; 1: 180–186 [PubMed] [Google Scholar]
  • 22. Selzer A, Wray HW: Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17–26 [DOI] [PubMed] [Google Scholar]
  • 23. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R: Regional attitudes of generalists. specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156: 2553–2562 [PubMed] [Google Scholar]
  • 24. Radford MD, Evans DW: Long‐term results of DC reversion of atrial fibrillation. Br Heart J 1968; 30: 91–96 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. Circulation 1990; 82: 1106–1116 [DOI] [PubMed] [Google Scholar]
  • 26. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20: 527–532 [DOI] [PubMed] [Google Scholar]
  • 27. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimle A, Walden JA, Tillisch JH: Improving survival for patients with atrial fibrillation and advance heart failure. J Am Coll Cardiol 1996; 28: 1458–1463 [DOI] [PubMed] [Google Scholar]
  • 28. Faber TS, Zehender M, Van de Loo A, Hohnloser S, Just H: Torsade de pointes complicating drug treatment of low‐malignancy forms of arrhythmia: Four case reports. Clin Cardiol 1994; 17: 197–202 [DOI] [PubMed] [Google Scholar]
  • 29. Strasberg B, Sclarovsky S, Erdberg A, Duffy CE, Lam W, Swiryn S, Agmom J, Rosen KM: Procainamide‐induced polymorphic venricular tachycardia. Am J Cardiol 1981; 47: 1309–1314 [DOI] [PubMed] [Google Scholar]
  • 30. Riccioni N, Castiglioni M, Bartolomei C: Disopyramide‐induced QT prolongation and ventricular tachyarrhythmia. Am Heart J. 1983; 105: 870–871 [DOI] [PubMed] [Google Scholar]
  • 31. Stralmann HG, Waller KE, Kennedy HL: Torsade de pointes associated with elevated N‐acetylprocainamide levels. Am Heart J 1985; 109: 375–376 [DOI] [PubMed] [Google Scholar]
  • 32. Herre JM, Thompson JA: Polymorphic ventricular tachycardia and ventricular fibrillation due to N‐acetyl procainamide. Am J Cardiol 1985; 55: 227–228 [DOI] [PubMed] [Google Scholar]
  • 33. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation 1989; 80: 1557–1570 [DOI] [PubMed] [Google Scholar]
  • 34. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 77: 53A–59A [DOI] [PubMed] [Google Scholar]
  • 35. Stelfox HT, Chua A, O'Rourke K, Detsky AS: Conflict of interest in the debate over calcium‐channel antagonists. N Engl J Med 1998; 338: 101–106 [DOI] [PubMed] [Google Scholar]
  • 36. Falk RH: Flecainide‐induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111: 107–111 [DOI] [PubMed] [Google Scholar]
  • 37. Sihm I, Hansen FA, Rasmussen J, Pedersen AK, Thygesen K: Flecainide acetate in atrial flutter and fibrillation. Eur Heart J 1990; 11: 145–148 [DOI] [PubMed] [Google Scholar]
  • 38. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157–1159 [DOI] [PubMed] [Google Scholar]
  • 39. Ellenbogen KA, Wood MA, Stambler BS: Procainamide: A perspective on its value and danger. Heart Dis & Stroke 1993; 2: 473–476 [PubMed] [Google Scholar]
  • 40. Landrum EM, Siegert EA, Hanlon JT, Currie MS: Prolonged thrombocytopenia associated with procainamide in an elderly patient. Ann Pharmacol 1994; 28: 1172–1176 [DOI] [PubMed] [Google Scholar]
  • 41. Cardiac Arrhythmia Suppression Trial : Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412 [DOI] [PubMed] [Google Scholar]
  • 42. Davison R, Hartz R, Kaplan K, Parker M, Feiereisel P, Michaelis L: Prophylaxis of supraventricular tachyarrhythmia after coronary by‐pass surgery with oral verapamil: A randomized, double‐blind trial. Ann Thor Surg 1985; 39: 336–339 [DOI] [PubMed] [Google Scholar]
  • 43. Heywood JT: Calcium channel blockers for heart rale control in atrial fibrillation complicated by congestive heart failure. Can J Cardiol 1995; 11: 823–826 [PubMed] [Google Scholar]
  • 44. Olshansky B: Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol 1996; 78 (8A): 27–34 [DOI] [PubMed] [Google Scholar]
  • 45. McAlister HF, Luke RA, Whitlock RM, Smith WM: Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation after cardiac operations. J Thorac Cardiovasc Surg 1990; 99: 911–918 [PubMed] [Google Scholar]
  • 46. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL: Acute treatment of recent‐onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized digoxin‐controlled study. Eur Heart J 1995; 16: 521–528 [DOI] [PubMed] [Google Scholar]
  • 47. Galve E, Rius, T , Ballester R, Artaza MA, Arnau JM, Garcia‐Corado D, Soler‐Soler J: Intravenous amiodarone in treatment of recent‐onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996; 27: 1079–1082 [DOI] [PubMed] [Google Scholar]
  • 48. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP Lie KI : Low‐dose amiodarone for maintenance of sinus rhythm after cardioversion for atrial fibrillation. J Am Med Assoc 1992; 267: 3289–3293 [PubMed] [Google Scholar]
  • 49. Zdrenghea D, Banu E, Bogdan E, Beudean M: The effect of low‐dose amiodarone in prevention of paroxysmal atrial fibrillation. Rom J Intern Med 1996; 34: 199–204 [PubMed] [Google Scholar]
  • 50. Singh S, Sainl RK, DiMarco J, Kluger J, Gold R, Chen YW: Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol 1991; 68: 1227–1230 [DOI] [PubMed] [Google Scholar]
  • 51. Anderson JL: Acute treatment of atrial fibrillation and flutter. Am J Cardiol 1996; 78: 17–21 [DOI] [PubMed] [Google Scholar]
  • 52. Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449–1457 [PubMed] [Google Scholar]
  • 53. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A: Antithrombotic therapy in atrial fibrillation. Chest 1995; 108: 352S–359S [DOI] [PubMed] [Google Scholar]
  • 54. Stroke Prevention in Atrial Fibrillation II Study: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet 1994; 343: 687–691 [PubMed] [Google Scholar]
  • 55. Golzari H, Cebui RD, Bahler RC: Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996; 125: 311–323 [DOI] [PubMed] [Google Scholar]
  • 56. Waktare JEP, Camm AJ: Atrial fibrillation begets trouble. Heart 1997; 77: 393–394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Peters KG, Kienzie MG: Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Aw J Med 1988; 85: 242–244 [DOI] [PubMed] [Google Scholar]
  • 58. Grogan M, Smith HC, Gersh BJ, Wood DL: Left ventricular dysfunction due to atrial fibrillation in patients originally believed to have idiopathic cardiomyopathy. Am J Cardiol 1992; 69: 1570–1573 [DOI] [PubMed] [Google Scholar]
  • 59. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1990; 323: 1509–1511 [DOI] [PubMed] [Google Scholar]
  • 60. Stroke Prevention in Atrial Fibrillation Study : Final results. Circulation 1991; 84: 527–539 [DOI] [PubMed] [Google Scholar]
  • 61. Grace AA, Camm AJ: Quinidine. N Engl J Med 1998; 338: 35–45 [DOI] [PubMed] [Google Scholar]
  • 62. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerberg RJ, Naccerelli GV, Wyse DG: Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology. American Heart Association. Circulation 1996; 93: 1262–1277 [DOI] [PubMed] [Google Scholar]
  • 63. Prystowsky EN: Proarrhythmia during drug treatment of supraventricular tachycardia: Paradoxical risk of sinus rhythm for sudden death. Am J Cardiol 1996; 78: (suppl 8A) 35–41 [DOI] [PubMed] [Google Scholar]
  • 64. Sopher SM, Camm AJ: Atrial fibrillation: Maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A–37A [DOI] [PubMed] [Google Scholar]
  • 65. Feld GK, Fleck P. Fujimura O, Prothro DL, Bahnson TD, Ibarra M: Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994; 90: 2299–2307 [DOI] [PubMed] [Google Scholar]
  • 66. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Marady F: Radiofrequency catheter modification of atrioventricular conduction to control the ventricular response during atrial fibrillation. N Engl J Med 1994; 331: 910–917 [DOI] [PubMed] [Google Scholar]
  • 67. Morady F, Hasse C, Strickberger SA, Man KC, Daoud E, Bogun F, Goyal R, Harvey M, Knight BP, Weiss R, Bahu M: Long‐term follow‐up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 1997; 29: 113–121 [DOI] [PubMed] [Google Scholar]
  • 68. Kay GN, Bubien RS, Epstein AE, Plumb PJ: Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988; 62: 741–744 [DOI] [PubMed] [Google Scholar]
  • 69. Twidale N, Sutton K, Bartlett L, Dooley A, Winstanley S, Heddle W, Hassam H, Koutsounis H: Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug‐refractory atrial fibrillation. PACE 1993; 16: 1275–1284 [DOI] [PubMed] [Google Scholar]
  • 70. Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, Acquarone S: Assessment of atrioventricular junction ablation and DDDR mode‐switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: A randomized controlled study. Circulation 1997; 96: 2617–2624 [DOI] [PubMed] [Google Scholar]
  • 71. Carlson MD, Biblo LA: Atrial defibrillation. New frontiers. Cardiol Clin 1996; 14: 607–622 [DOI] [PubMed] [Google Scholar]
  • 72. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN: Long‐term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76: 47–50 [DOI] [PubMed] [Google Scholar]
  • 73. Mackstaller LL, Alpert JS: Atrial fibrillation: A review of mechanisms, etiology, and therapy. Clin Cardiol 1997; 20: 640–650 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Podrid PJ: Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995; 122: 689–700 [DOI] [PubMed] [Google Scholar]
  • 75. Nademanee K, Singh BN, Hendrickson JA, Intarachot V, Lopez B, Feld G, Cannom DS, Weiss JL: Amiodarone in refractory life‐threatening ventricular arrhythmias. Ann Intern Med 1983; 98: 577–584 [DOI] [PubMed] [Google Scholar]
  • 76. Mason JW: Amiodarone. N Engl J Med 1987; 16: 455–466 [DOI] [PubMed] [Google Scholar]
  • 77. Nademanee K: The amiodarone odyssey. J Am Coll Cardiol 1992; 20: 1063–1065 [DOI] [PubMed] [Google Scholar]
  • 78. Middlekauff HR, Wiener I, Stevenson WG: Low‐dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72: 75F–81F [DOI] [PubMed] [Google Scholar]
  • 79. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone‐associated proarrhythmic effects. A review with specific references to torsade de pointes tachycardia. Ann Intern Med 1994; 121: 529–535 [DOI] [PubMed] [Google Scholar]
  • 80. Hohnloser SH, Woosley RL: Sotalol. N Engl J Med 1994; 331: 31–38 [DOI] [PubMed] [Google Scholar]
  • 81. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L: Comparison of sotalol with digoxin‐quinidine for conversion of acute atrial fibrillation to sinus rhythm (the sotalol‐digoxin‐quinidine trial). Am J Cardiol 1995; 76: 495–498 [DOI] [PubMed] [Google Scholar]
  • 82. Lehman MH, Hardy S, Archibald D, Quart B, MacNeil DJ: Sex difference in risk of torsade de pointes with d, l‐sotalol. Circulation 1996; 94: 2534–2541 [DOI] [PubMed] [Google Scholar]
  • 83. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R: The long QY syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115–177 [DOI] [PubMed] [Google Scholar]
  • 84. Julian DG, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1: 1142–1147 [DOI] [PubMed] [Google Scholar]
  • 85. Kowey PR, Vander Lugt JT, Luderer JR: Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation. Am J Cardiol 1996; 78 (suppl8A): 46–52 [DOI] [PubMed] [Google Scholar]
  • 86. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, and the Ibutelide Repeat Dose Study Investigators : Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–1621 [DOI] [PubMed] [Google Scholar]
  • 87. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82 [DOI] [PubMed] [Google Scholar]
  • 88. Wilson JS, Podrid PJ: Side effects from amiodarone. Am Heart J 1991; 121: 158–171 [DOI] [PubMed] [Google Scholar]
  • 89. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R: Randomized trial of low‐dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–498 [DOI] [PubMed] [Google Scholar]
  • 90. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ: Randomized trial of effect of amiodarone on mortality in patients with left‐ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667–674 [DOI] [PubMed] [Google Scholar]
  • 91. Richer M, Robert S: Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother 1995; 29: 582–586 [DOI] [PubMed] [Google Scholar]
  • 92. Tosetti C, Ongari M, Evangelisti A, Lolli R, Napoli A: Acute hepatotoxicity from amiodarone. Minerva Med 1995; 86: 387–390 [PubMed] [Google Scholar]
  • 93. AFFIRM : Atrial fibrillation follow‐up investigation of rhythm management. Am J Cardiol 1997; 79: 1198–1202 [PubMed] [Google Scholar]
  • 94. Brodsky MA, Podrid PJ, Chun JG: Should physicians participate in affirming the best approach to atrial fibrillation management? Am J Cardiol 1996; 78: 1112–1153 [PubMed] [Google Scholar]
  • 95. Blackshear JL, Kopecky SL, Litin SC, Safford RE, Hammill SC: Management of atrial fibril latin in adults: Prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc 1996; 71: 150–160 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES